09:44 AM EST - Avant Technologies Inc : Along with its partner, Ainnova Tech, Inc., today announced that the Company has started designing its clinical trial protocol ahead of a pre-submission meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting is to request guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, and Ainnova's clinical trial will culminate in the submission of an FDA 510(k) to obtain clearance from the regulatory agency to market its technology. Avant Technologies Inc
shares O.AVAI are trading up one cent at $0.50.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=AVAI&qmodStoryID=7188291357506925
